Human Oncology & Pathogenesis Program

The Sarat Chandarlapaty Lab

Sarat Chandarlapaty, MD, PhD

Naddisy Foundation Chair in Breast Cancer Research

Professor of Medicine, Weill Cornell Medical College and Weill Cornell Cell and Developmental Biology Program

My lab focuses on understanding the regulation of growth factor signal transduction pathways that are aberrantly activated in cancers, with a focus on those implicated in breast cancer pathogenesis.

View Lab Overview

Publications Highlights

Will M, Liang J, Metcalfe C, Chandarlapaty S. Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nat Rev Cancer. 2023 Oct;23(10):673-685. doi: 10.1038/s41568-023-00604-3. Epub 2023 Jul 27. Review. PubMed PMID: 37500767; PubMed Central PMCID: PMC10529099.

Li Q, Jiang B, Guo J, Shao H, Del Priore IS, Chang Q, Kudo R, Li Z, Razavi P, Liu B, Boghossian AS, Rees MG, Ronan MM, Roth JA, Donovan KA, Palafox M, Reis-Filho JS, de Stanchina E, Fischer ES, Rosen N, Serra V, Koff A, Chodera JD, Gray NS, Chandarlapaty S. INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. Cancer Discov. 2022 Feb;12(2):356-371. doi: 10.1158/2159-8290.CD-20-1726. Epub 2021 Sep 20. PubMed PMID: 34544752; PubMed Central PMCID: PMC8831444.

Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer. 2020 Apr;1(4):382-393. doi: 10.1038/s43018-020-0047-1. Epub 2020 Mar 23. PubMed PMID: 32864625; PubMed Central PMCID: PMC7450824.

Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell. 2018 Dec 10;34(6):893-905.e8. doi: 10.1016/j.ccell.2018.11.006. PubMed PMID: 30537512; PubMed Central PMCID: PMC6294301.

Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822. Epub 2013 Nov 3. PubMed PMID: 24185512; PubMed Central PMCID: PMC3903423.

View All Publications

People

Sarat Chandarlapaty, MD, PhD

Naddisy Foundation Chair in Breast Cancer Research

Professor of Medicine, Weill Cornell Medical College and Weill Cornell Cell and Developmental Biology Program

Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.
PhD, University of North Carolina

[email protected]: Email Address
View physician profile: Physician profile

Members

Wanyi Chen

WGS Student

Payal Patel

Graduate Student

Allen Zhu

Research Technician

Lab Alumni

Bo Liu, Research Associate — Bo Liu
Research Associate

Ramya Segu Rajappachetty
Research Technician Sr.

ChengCheng Yang
Graduate Research Assistant

Lab Affiliations

Achievements

Professor of Medicine, Weill Cornell Medical College and Weill Cornell Cell and Developmental Biology Program
Member Memorial Sloan Kettering Cancer Center, Department of Medicine and Human Oncology and Pathogenesis Program

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

[email protected]

Lab Head Email
Lab Twitter

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sarat Chandarlapaty discloses the following relationships and financial interests:

AstraZeneca
Professional Services and Activities
Blueprint Medicines
Professional Services and Activities
Casdin Capital, LLC
Professional Services and Activities
Daiichi Sankyo
Professional Services and Activities
eFFECTOR Therapeutics
Equity; Professional Services and Activities
Eli Lilly and Company
Professional Services and Activities (Uncompensated)
Encore Medical Education
Professional Services and Activities
Genesis Therapeutics
Professional Services and Activities

Gerson Lehrman Group
Professional Services and Activities
Novartis
Professional Services and Activities
Nuvalent, Inc.
Professional Services and Activities
Odyssey Biosciences
Equity; Fiduciary Role / Position; Intellectual Property Rights
Prelude Therapeutics
Professional Services and Activities
SAGA Diagnostics
Professional Services and Activities
Springer Nature Limited
Professional Services and Activities
Totus Medicines Inc.
Equity

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures